STAT

DECEMBER 22, 2023

“I do not believe this particular change will have any bearing on patient care,” said Saad Usmani, a myeloma physician and cell therapist at Memorial Sloan Kettering who has also studied Carvykti.

Labelling 111

Labelling Chemotherapy FDA Patient Care 111

Pharmaceutical Technology

MAY 22, 2023

The US Food and Drug Administration (FDA) has granted approval to AbbVie and Genmab ‘s Epkinly (epcoritamab-bysp) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients. The FDA approval of Epkinly represents a new treatment mechanism of action for third-line DLBCL patients. “As

FDA 52

FDA Adverse Reactions Chemotherapy Patient Care 52

The Checkup by Singlecare

AUGUST 8, 2024

A medication shortage occurs when the demand for a drug is greater than the supply, according to the Food and Drug Administration (FDA). The FDA tracks drug shortages at the national level by obtaining information from drug manufacturers about their ability to produce medications. Many factors cause medication shortages.

Compounding 52

Compounding FDA Compounding Pharmacies Community Pharmacies 52

Pharmacy Times

JUNE 19, 2025

1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.

Chemotherapy 73

Chemotherapy Compounding Pharmacies Hospitals Immunization 73

The Thyroid Pharmacist

SEPTEMBER 20, 2024

Plecanatide : This is one of the newest medications for IBS-C that has been approved by the FDA. Plecanatide is recommended by the ACG for overall symptomatic improvement in IBS-C patients. Lubiprostone : This medication is often recommended for symptomatic improvement in IBS-C patients. 2020;12(1):205. Published 2020 Jan 13.

Health and Personal Care Stores 84

Health and Personal Care Stores Chemotherapy Immunization Compounding 84

Pharmacy Times

JUNE 10, 2025

Meloxicam injection (Xifyrm; Azurity Pharmaceuticals, Inc) received FDA approval for use in adults for the management of moderate-to-severe pain, either alone or in combination with non-steroidal anti-inflammatory drug (NSAID) analgesics. Designing the ideal perioperative pain management plan starts with multimodal analgesia. August 24, 2018.

FDA 73

FDA HIV Treatment and Prevention Agents Compounding Pharmacies Hospitals 73

Pharmacy Times

JUNE 20, 2025

Kalis, PharmD, BCOP Key Takeaways Oncology pharmacy's complexity outpaces the generalist model, necessitating specialization for effective patient care and operational efficiency. These are all important and necessary topics that help cancer centers run effectively and deliver exceptional patient care.

Compounding 107

Compounding Compounding Pharmacies Patient Care Immunization 107